Project archive

The aim of the project PhagoFlow in Braunschweig is to determine the infrastructural requirements for magistral production of phages in Germany to enable treatment of patients with wound infections of the extremities.

During many years of research on malignant diseases, scientists at Fraunhofer ITEM in Regensburg have gained special expertise in analyzing single cells from liquid biopsies. With some minor adjustments, they can apply – and have already applied – the established, partly automated technologies for single-cell DNA and RNA analysis from clinical samples to other cell types in order to characterize these in more detail and to make use of the information thus obtained, for example to identify biomarkers.

Starting in January 2019, 13 partners from 7 European countries, including research institutes, universities and small and medium-sized enterprises, have been collaborating in the Horizon 2020 project MDOT (Medical Device Obligations Taskforce). This project is being coordinated by Fraunhofer ITEM, with a grant size of 8.3 million euros and 5 years overall duration.

In this project commissioned by BAuA (Federal Institute for Occupational Safety and Health) inhalation and dermal exposure dring biocidal foaming activities are investigated.

Researchers of the Fraunhofer ITEM have developed a system that optically detects neonatal breathing and releases the aerosol directly at the patient interface in a breath-triggered manner.

In an in vivo study conducted at Fraunhofer ITEM, the toxic potential of niobium pentoxide towards the respiratory tract was investigated.

With the aim of identifying specific biomarkers for teratogenic effects at developmental stages, Fraunhofer ITEM researchers have developed an analysis pipeline in the CEFIC-LRI project ZET-O-MAP that links morphological changes with alterations in gene expression.

Cell painting with subsequent automated image analysis can identify more than 5000 cellular features, forming a “cellular fingerprint”.

In the Project MutaMind researchers aim to better understand the processes contributing to the mutagenicity of NAs and to develop custom-tailored in-vitro tools.

To enable better assessment of the safety also of future drugs, Fraunhofer ITEM researchers are developing innovative model systems for assessing immunomodulatory therapeutics.